ReviewMolecular imaging and biology2026
Listening to Immunotherapy - Ultrasound and Photoacoustic Imaging Strategies to Guide and Enhance Cancer Treatments.
Review in Molecular imaging and biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapies are transformative strategies in modern oncology, utilizing the body's own immune system to stimulate and enhance the antitumor immune response. Successful immunotherapies require precise delivery, real-time monitoring of immune reactions, and flexible treatment strategies that can adapt to patient-specific complexities. These conditions underscore the need for noninvasive, longitudinal imaging approaches to understand therapy progress and maximize response towards precision immunotherapies. Photoacoustic (PA) imaging, especially when integrated with ultrasound (US), is a powerful modality that is gaining momentum in the immunoimaging space. PA imaging enables label-free assessment of functional biological parameters using endogenous chromophores, while engineered exogenous contrast agents extend its capabilities for molecular and cellular imaging towards theranostic applications. These advances allow visualization of immune activity, therapeutic distribution, and treatment-induced microenvironmental changes in real-time. In this review, we focus on the integral role of US/PA imaging in guiding, optimizing, and advancing cancer immunotherapy. This review begins by outlining label-free imaging techniques and the use of exogenous contrast agents as theranostic nanoplatforms in cancer immunotherapies. Following this foundation, we explore US/PA imaging in immunotherapies, emphasizing photoimmunotherapy, adoptive cell immunotherapy, immune checkpoint blockade, and focused ultrasound mediated immunomodulation. Additionally, we highlight complementary multimodal imaging approaches that expand the scope of US/PA guided immunotherapy. Finally, we address key translational challenges, emerging innovations, and future directions for translating US/PA into routine clinical practice.
Indexed as
Identifiers
42560395What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.